Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful conscientiously but unsuccessfully to create a single therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my last several shares. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a highly marketing image in the Uptick Newswire employment interview that I came away with a bad impression of the company.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, yet the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 million transfers ownership of this technology as well as connected intellectual property from Progenics to CytoDyn, as well as roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) as well as the first new drug program approval ($five million), and even royalty payments of five percent of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and many therapies, it’s this individual treatments as well as a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

Its opening banner on its website (below) shows an active company with diverse interests albeit centered on leronlimab, several illness sorts, multiple presentations and multiple publications.

Might all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself through the really beginning of the interest of mine in this particular company. Judging by the multiples of a huge number of diverse commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or even some could say cult stock. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *